Keros Therapeutics Inc [KROS] stock is trading at $16.2, up 0.19%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KROS shares have gain 6.44% over the last week, with a monthly amount glided 0.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Keros Therapeutics Inc [NASDAQ: KROS] stock has seen the most recent analyst activity on October 20, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $26. Previously, BofA Securities downgraded its rating to Neutral on June 10, 2025, and kept the price target unchanged to $18. On January 21, 2025, downgrade downgraded it’s rating to Neutral. Wedbush downgraded its rating to a Neutral but stick to its price target of $15 on January 17, 2025. Oppenheimer reiterated its recommendation of a Outperform and reduced its price target to $63 on December 16, 2024. Guggenheim downgraded its rating to Neutral for this stock on December 16, 2024. In a note dated December 13, 2024, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $100 to $47.
Keros Therapeutics Inc [KROS] stock has fluctuated between $9.12 and $72.37 over the past year. Currently, Wall Street analysts expect the stock to reach $102.6 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $16.2 at the most recent close of the market. An investor can expect a potential return of 533.33% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Keros Therapeutics Inc [NASDAQ:KROS] reported sales of 246.72M for the trailing twelve months, which represents a growth of 3575.77%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.29%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.1 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.81 points at the first support level, and at 15.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.67, and for the 2nd resistance point, it is at 17.14.
Ratios To Look Out For
For context, Keros Therapeutics Inc’s Current Ratio is 29.86. In addition, the Quick Ratio stands at 29.86 and the Cash Ratio stands at 28.78. Considering the valuation of this stock, the price to sales ratio is 2.00, the price to book ratio is 0.94 and price to earnings (TTM) ratio is 10.50.
Transactions by insiders
Recent insider trading involved Pontifax Management 4 G.P. (20, 10% Owner, that happened on Oct 15 ’25 when 4.79 million shares were sold. 10% Owner, ADAR1 Capital Management, LLC completed a deal on Oct 15 ’25 to sell 5.39 million shares. Meanwhile, Affiliate Rovaldi Christopher bought 85306.0 shares on Sep 12 ’25.
